文献速递主动脉外科

药物治疗对主动脉炎主动脉瘤修复术后远期并发症和死亡率的影响

Impact of Medical Therapy on Late Morbidity and Mortality After Aortic Aneurysm Repair for Aortitis.
PubMed 文献 · Ann Thorac Surg · 2018-02-02

回顾性分析186例非感染性主动脉炎患者行择期升主动脉瘤修复术后的远期结局。15年总死亡率为88.3%,10年总再手术率为28.2%。主动脉炎系统性后遗症与远期再手术风险增加相关(未校正HR 3.59),但糖皮质激素治疗未与后续死亡或再手术明显相关。

要点

  • 15年总死亡率88.3%,10年总再手术率28.2%。
  • 系统性后遗症与远期再手术风险增加相关(未校正HR 3.59,95%CI 1.40-9.18)。
  • 糖皮质激素治疗未与后续死亡或再手术相关。

核心结论

  • 主动脉炎继发的系统性病变与远期主动脉再手术风险增加相关,但糖皮质激素治疗非感染性主动脉炎未明显影响生存或再手术需求。

研究设计与样本

  • 回顾性队列研究,纳入1955年1月至2012年12月期间186例非感染性主动脉炎患者(中位年龄73.9岁,女性120例),均在择期升主动脉瘤修复术后接受分析,采用界标分析比较孤立性主动脉炎与主动脉炎系统性后遗症患者及糖皮质激素治疗后的结局。

主要发现

  • 15年总死亡率为88.3%,10年总再手术率为28.2%。
  • 远期死亡率随手术时年龄较大(HR 1.62,95%CI 1.25-2.11,P<0.001)、冠心病(HR 1.94,95%CI 1.25-3.01,P=0.003)、外周血管病(HR 1.79,95%CI 1.09-2.94,P=0.02)及术前怀疑主动脉炎(HR 4.90,95%CI 1.96-12.26,P<0.001)而增加。
  • 再手术率增加与冠心病(HR 2.69,95%CI 1.17-6.17,P=0.02)和外周血管病(HR 3.92,95%CI 1.71-8.94,P=0.001)相关。
  • 在术后6个月未再手术的患者中,主动脉炎系统性后遗症与再手术风险显著相关(未校正HR 3.59,95%CI 1.40-9.18,P=0.008)。
  • 糖皮质激素治疗未与后续死亡或再手术相关。

关键数值与推荐

  • 15年总死亡率为88.3%,10年总再手术率为28.2%。
  • 在术后6个月未再手术的患者中,主动脉炎系统性后遗症与再手术风险显著相关(未校正HR 3.59,95%CI 1.40-9.18,P=0.008)。
  • 糖皮质激素治疗未与后续死亡或再手术相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with active aortitis who undergo repair of ascending aortic aneurysms have an increased risk of late reoperation and decreased late survival. We aimed to determine the reasons for these poor outcomes and the influence of medical management. METHODS: We reviewed records of 186 patients (median age 73.9 years; 120 women) with noninfectious aortitis after elective ascending aortic aneurysm repair (January 1955 through December 2012). Landmark analysis was used to compare outcomes in patients with isolated aortitis versus with systemic sequelae of aortitis along with outcomes of treatment with glucocorticoids. RESULTS: At 15 years, the overall mortality was 88.3%; at 10 years, the overall reoperation rate was 28.2%. Long-term mortality increased with older age at surgery (hazard ratio [HR] 1.62, 95% confidence interval [CI]: 1.25 to 2.11, p < 0.001), coronary artery disease (HR 1.94, 95% CI: 1.25 to 3.01, p = 0.003), peripheral vascular disease (HR 1.79, 95% CI: 1.09 to 2.94, p = 0.02), and preoperative suspicion of aortitis (HR 4.90, 95% CI: 1.96 to 12.26, p < 0.001). Increased reoperation rate was associated with coronary artery disease (HR 2.69, 95% CI: 1.17 to 6.17, p = 0.02) and peripheral vascular disease (HR 3.92, 95% CI: 1.71 to 8.94, p = 0.001). Among patients free of reoperation at 6 months, systemic sequelae of aortitis were found to be significant, with an unadjusted hazard ratio of 3.59 (95% CI: 1.40 to 9.18, p = 0.008). Treatment with glucocorticoids was not associated with subsequent mortality or reoperation. CONCLUSIONS: The development of systemic illness secondary to aortitis was associated with increased risk of late aortic reoperations. However, glucocorticoid treatment of noninfectious aortitis did not clearly influence survival or need for reoperation.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Prasad A, Helder MRK, Lahr BD, et al. Impact of Medical Therapy on Late Morbidity and Mortality After Aortic Aneurysm Repair for Aortitis. Ann Thorac Surg. 2018. PMID: 29408240. doi:10.1016/j.athoracsur.2018.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。